The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression – an overlapping myeloproliferative disorder or two distinct diseases? - case report

Ursuleac I*, Colita AC*, Adam T*** ****, Jardan C*, Ilea A*****, Coriu D* **

*“Stefan Berceanu” Center of Haematology and Medullary Transplant, Fundeni Clinical Institute, Bucharest
**“Carol Davila” University of Medicine and Pharmacy, Bucharest
***Internal Medicine Clinic, Clinical Emergency Hospital, Constanta
****Faculty of Medicine, Ovidius University, Constanta
*****Ritus Biotec Laboratory, Codlea, Brasov

Correspondence to: Iulia Ursuleac
Fundeni Hematology Clinic, Bucharest,
258 Fundeni Road, code 022328, District 2, Bucharest, Romania
E-mail: iuliaursuleac@yahoo.com

Received: September 17th, 2012 – Accepted: February 14th, 2013

Abstract
The concomitant occurrence of JAK2V617F mutation and BCR/ABL translocation is a rare event. It is unclear if this is a result of the clonal evolution or a separately emergence of two clones and if it could lead to the progression to a more aggressive phase of the disease. We present the case of a 61-year-old man diagnosed and treated for polycythaemia vera for 7 years, which evolved into chronic myeloid leukemia BCR/ABL positive and with JAK2V617F mutated clone, that became dominant after an effective treatment with Imatinib.

Keywords: Chronic myeloid leukemia, polycythemia vera, BCR/ABL translocation and JAK2V617F mutation coexpression, phenotypic expression

Abbreviations: WHO - World Health Organisation; CML - chronic myeloid leukemia; MPN - myeloproliferative neoplasms; PCR- polymerized chain reaction; TKI – tyrosine kinase inhibitors; PV - polycythemia vera; ET- essential thrombocythemia; PMF - primary myelofibrosis; ESR - erythrocyte sedimentation rate; WBC - white blood cell count; LDH - lacticodehydrogenase; ALP - alkaline leucocyte phosphatise

Introduction
Myeloproliferative disorders are a heterogeneous group of diseases that include polycythemia vera, primary myelofibrosis, essential thrombocytopenia. Since the discovery of BCR/ABL translocation and the specific cytogenetic marker, Philadelphia chromosome, resulted from the translocation t(9;22)(q34;q11), chronic myeloid leukemia is a separate entity and a distinct disease. It is also a model for a successfully targeted therapy, because of the Imatinib specific effect against tyrosine kinase activity of the product regarding the fusion gene BCR/ABL. The WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues include polycythemia vera, primary myelofibrosis, essential thrombocythemia in the group of myeloproliferative neoplasms (MPN) [1]. All of these diseases are caused by clonal injuries and transformation of hematopoietic stem cell and because of the result of an unusual, affected haematopoiesis they can share clinical features or overlap symptoms during their evolution and progression to more aggressive patterns, like acute leukemia.

Background
Acquired mutations of genes are necessary, but not sufficient conditions for the achievement of a malignant phenotype. Their detection contributes to defining a specific disease or for monitoring the evolution and the treatment response. In clinical practice, the real time PCR assay has proven its utility for predicting the response to TKI therapy in CML. Among the mutations associated with MPNs, JAK2V617F is the commonest, founded in about 95% cases of PV, 50-65% cases of ET and PMF and up to 50% cases of anaemia with ringed sideroblasts and thrombocytosis. JAK2V617F mutation is also present in 3-9% cases of chronic myelomonocytic leukemia [2]. There is a strong correlation between the detection of JAK2 mutation and the diagnostic of PV, as in the case of CML and BCR/ABL translocation. The JAK2 mutation leads to the activation of the JAK/STAT signalling pathway (signal transducer and activator of transcription), resulting in cellular proliferation, resistance
to apoptosis and progression to overt MPNs. In some cases, two or more mutations were described in the same patient, but the phenotypic expression may be mute. The concomitancy of JAK2V617F mutation and BCR/ABL translocation in the same individual is uncommon. There were described cases of CML in advanced stages and concomitant mutations as TET2, CBL, ASXL1, IDH1 as signals for progressive evolution [3]. In a correspondence published in Blood, no118, 2011, a group of Italian authors analysed the frequency of the concomitant, double mutated phenotype JAK2V617F and BCR/ABL positive on a large cohort of 314 patients diagnosed with typical CML and found 8 cases of chronic phase CML patients who harbour both JAK2V617F mutation and BCR/ABL translocation [3,4]. We report the case of a 61 years old man, diagnosed in 2003 in Fundeni Clinic of Haematology with polycythemia vera based on clinical and biological standard criteria [5]. The clinical and laboratory findings are presented in Table 1.

### Table 1. Laboratory findings at diagnosis of PV state

| Laboratory findings                  | Values | Normal ranges          |
|-------------------------------------|--------|------------------------|
| Haemoglobin                         | 20.8 g/dl | 12-16 g/dl            |
| Hematocrit                          | 61.5%  | 33-48%                 |
| WBC                                 | 20×10⁹ mmc | 4-10×10⁹/mmcc       |
| Neutrophils                         | 76%    | 35-45%                 |
| Eosinophils                         | 1%     | 0-0.5%                 |
| Basophils                           | 1%     | 0- 1%                  |
| Lymphocytes                         | 11%    | 25-35%                 |
| Monocytes                           | 7%     | 3-7%                   |
| Platelets                           | 750 × 10⁹/mmcc | 150-450 × 10⁹/mmcc |
| ESR                                 | 1 mm/hour | 3-16 Mui/ml         |
| Seric erthropoietinum               | 1.2 mui/ml | 3-16 Mui/ml         |
| Oxygen saturation blood             | 96.2%  | 90-120µg/dl           |
| Coagulation tests, biochemistry     | normal |                        |
| Aggregometry                        | Hypoaggregation at epinephrine, ADP | |

Interestingly, the patient had a son diagnosed 5 years before with Hodgkin’s Lymphoma (mixed cellularity) stage IIIIB successfully treated and alive, in complete remission at the time of this report and a brother diagnosed with an anaplastic B cell Lymphoma stage IVB, with deleterious evolution. At the time of diagnostic, for technical reasons, we cannot perform the screening for JAK2V617F mutation. He was treated with phlebotomies and Hydroxyurea for 7 years with a good clinical and haematological condition. In October 2010, he came again in our clinic with pallor, dyspnea on exertion, hepatosplenomegaly (5 centimetres below costal margin) and haematological tests highly suggestive for chronic myeloid leukemia pattern. Laboratory findings are presented in Table 2.

### Table 2. Laboratory findings at diagnosis of CML state

| Laboratory findings                  | Values | Normal ranges          |
|-------------------------------------|--------|------------------------|
| Haemoglobin                         | 9 g/dl | 12-16 g/dl            |
| Hematocrit                          | 28%    | 33-48%                 |
| WBC & differentials                 | 108×10⁹/mmcc | 4 -10 ×10⁹/mmcc      |
| Blasts                              | 1%     | 0%                     |
| Promyelocytes                       | 1%     | 0%                     |
| Myelocytes                          | 10%    | 0%                     |
| Metamyelocytes                      | 6%     | 0%                     |
| Bands                               | 17%    | 1-3%                   |
| Neutrophils                         | 47%    | 35-45%                 |
| Eosinophils                         | 1%     | 0-0.5%                 |
| Basophils                           | 5%     | 0-1%                   |
| Lymphocytes                         | 6%     | 25-35%                 |
| Monocytes                           | 6%     | 3-7%                   |
| Platelets                           | 95×10⁹/mmcc | 150-450 × 10⁹/mmcc |
| LDH                                 | 1364   | <225U/I                |
| Vitamin B12 level                   | 1574 pg/ml | 190-910 pg/ml      |
| ALP                                 | 2      | 10-100                 |
| Iron level                          | 157.6 µg/dl | 90-120µg/dl        |

**FISH Analysis**

FISH analysis was performed on interphase cells using a dual-colour BCR/ABL probe, provided by Cytocell, Cambridge, UK (Fig. 1A and 1B).
Blood specimen was directly incubated in hypotonic KCl solution (0.075M) and then fixed (methanol: acetic acid - 3:1). After the slide preparation, slides were aged by incubation overnight at 37°C. FISH analysis of cultured BM sample was performed by using slides obtained by standard protocol for cytogenetic examination. Slides were dehydrated in an alcohol series. Co-denaturation was carried out for 2 minutes at 75°C, followed by overnight hybridisation at 37°C. After overnight hybridisation, slides were washed in 0.4X SSC at 73°C for 2 minutes and rinsed in 2 X SSC. Evaluation of the FISH signals was performed using a fluorescence microscope (AxioImager, Zeiss, Germany). 200 interphase nuclei were evaluated.

Conventional Karyotyping was also performed (Fig. 2).

Bone marrow sample was cultured using overnight and synchronized culture protocol and processed by conventional cytogenetic procedures with GTG banding [7]. 20 metaphases were analysed and the karyotype was described according to ISCN 2009 [8].

Molecular analysis for quantitative detection of BCR/ABL transcript was performed on peripheral blood on ABI 7700 instrument. Real Time PCR was performed using specific primers: for major BCR/ABL (p210) and minor (p190) and control gene ABL (Gabert et al. Leukemia 2003). The result was positive for major transcript BCR/ABL (p210) at a high level (100%). Additional tests for ETV6/ABL and FIP1L1/PDGFRA (del4q12) were negative. In the same sample we performed test for JAK2V617F mutation.

The detection of jak2V617F mutation was made according to ARMS method (Amplification refractory mutation system) described by Jones and col. in Blood, vol 6, no 6, September 2005 and the result was negative [9]. The bone marrow biopsy confirmed the diagnosis of chronic phase of chronic myeloid leukemia.

Clinical Outcome

After 6 months of cytoreductive treatment with Hydroxyurea the patient started treatment with Imatinib 400 mg/day with complete hematologic response and complete cytogenetic and molecular response, assessed according to ELN Recomendations at 6,12 and 18 months. FISH evaluation for t(9;22)(q34;q11) at 6 months was negative and the cytogenetic study (20 metaphases analysed) at 12 months was normal, without Philadelphia chromosome. At 18 months from starting Imatinib BCR/ABL transcript was undetectable. During the second year from the diagnostic of CML the patient was assessed monthly for hemograms and we observed a switch to polycythemic phenotype, with increasing in hematocrit and haemoglobin range, without signs of clonal evolution for CML: the BCR/ABL transcript level remain undetectable at 24 months, but it was detected JAK2V617F mutation in homozygous state (Fig. 3).

Genomic ADN was obtained using standard procedures of purification from peripheral blood with commercial kit QIAGEN, UK. Spectofotometric measurement was done with nanodrop ACT gene, USA.
the technique used two pairs of primers (tetraprimers), that amplify in the same reaction a control fragment and fragments corresponding to V617F mutation and to wild sequence (primers from Eurogentec, enzyme: HotStar Taq polymerase Qiagen, UK, 50bpDNA ladder Invitrogen, UK). Amplicons were control fragment (463bp) and fragments correspondent to V617F mutation (279bp) and wild sequence (229bp); they are revealed through electrophoresis in 3% agarose gel, colored with etilium bromide and visualized with UV transluminator. All samples have controls: positive (containing the mutated allele) and negative one (containing wild allele). The method has an internal and external validation.

Phlebotomies were added in the management of the patient. Nowadays, he is still on Imatinib, in good clinical and hematological condition, complete cytogenetic remission and undetectable level of BCR/ABL transcript.

Discussions

The described case illustrates the evolution and the clinical expression of two genetic abnormalities associated with two different myeloproliferative diseases. The occurrence of a single mutation is predictable for genomic instability [6]. Probably, the JAK2V617F mutation was the first one, since the diagnosis of PV and precedes the appearance of a new clone, with BCR (22q11.23)/ABL (9q34) translocation.

It may be a question to put: is there a mutagenic role for Hydroxyurea in this case? Another hypothesis may be that a subclone of BCR/ABL mutant stem cell emerged from a previous JAK2V617F mutated clone. During the evolution both phenotypic expressions appeared; when Imatinib treatment down regulated the BCR/ABL burden, the JAK2V617F mutated clone, less influenced, emerged and became dominant. This case illustrates the importance of performing molecular analysis in myeloproliferative diseases even more frequent when phenotypic expression is overlapped. The phenotypic heterogeneity results from accumulation of a pre-existing “silent” mutated clone or subsequent genetic events with genomic instability could lead to another abnormality.

Acknowledgements:
Didona Vasilache- Cytology Laboratory, Fundeni Clinical Institute
Camelia Dobrea- Hematopathology Laboratory, Fundeni Clinical Institute
Dumitru Jardan – for reviewing the manuscript

Disclosures: authors declare no disclosures
All authors have equal contribution.

References

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds): WHO classification of Tumours of Haematopoietic and Lymphoid Tissue, 2008, IARC, Lyon.
2. Rodgers G, Young N. Clinical Hematology, second edition, 2010, Lippincott, Williams &Wilkins.
3. Pieri L, Spolverini A, Scappini B, Occhini U, Birtolo S, Bosi A, Albano F, Fava C, Vannucchi AM. Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood. 2011; 118, 344-346.
4. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21):e198-e206.
5. Hoffman R, Boswell HS, in Hematology, by Hoffman and al. 1991, Ed. Churchill Livingstone, New York, 834.
6. Hussein K, Bock O, Theophile K, et al. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia. 2008;22(5):1059-1062.
7. Swansbury J. Methods in Molecular BiologyTM. Cancer Cytogenetics Methods and Protocols. Humana Press. 2003;220: 43-56.
8. Shaffer LG, Slovak ML, Campbell LJ. An International System for Human Cytogenetic Nomenclature. 2009.
9. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NCP. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005; 106: 2162-2168.